WA-SPIE
11.1.2023 19:04:37 CET | Business Wire | Press release
The Awards Committee of SPIE, the international society for optics and photonics, today announced the recipients of its prestigious annual awards. Honoring transformative advancements in a variety of professional areas — including medicine, astronomy, lithography, optical metrology, optical design, and community leadership — the Society's awards recognize technical accomplishments as well as committed service to SPIE and support of its organizational mission.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230110005929/en/
Graham Reed is the 2023 recipient of the SPIE Gold Medal. (Photo: Business Wire)
SPIE Gold Medal: Graham T. Reed
For sustained and ongoing leadership in the silicon photonics field, particularly in the area of silicon photonics modulators, mid-IR silicon photonics, and integrated lidar.
SPIE President's Award: Patrick Meyrueis
For bringing together the European optics and photonics community, for encouraging students toward leadership activities, and for commitment to the Society in launching SPIE Photonics Europe.
SPIE Directors' Award: John Greivenkamp
A posthumous recognition, for longstanding service and leadership, by generously giving time, energy, enthusiasm, and wisdom to improve the Society and its educational impact on the global photonics community.
SPIE Mozi Award: Burn J. Lin
For great scientific achievements in immersion lithography for semiconductor manufacturing.
SPIE Britton Chance Award in Biomedical Optics: David Benaron
For the development of technologies and the founding and co-founding of companies utilizing biomedical optics that advanced the fields of medicine and medical technology.
SPIE Biophotonics Technology Innovator Award: Wei Min
For innovative work in stimulated Raman scattering microscopy, and for creating a new field of biophotonics.
SPIE Rudolf and Hilda Kingslake Award in Optical Design: Wilhelm Ulrich
For decades of transformative design solutions across a broad range of optical products including photographic lenses, microscopy objectives, medical-imaging instrumentation, laser optics, metrology systems, and infrared optics.
SPIE Harrison H. Barrett Award in Medical Imaging: Elizabeth Krupinski
For pioneering work in medical-image perception, teleradiology, telepathology, and being among the first to carry out image-perception studies in the new domain of digital pathology.
SPIE Harold E. Edgerton Award in High-Speed Optics: Tara Fortier
For pioneering contributions to the development of frequency combs based on mode-locked lasers and their applications in metrology.
SPIE Dennis Gabor Award in Diffractive Optics: Aydogan Ozcan
For seminal contributions to holography, lens-free holographic microscopy, and computational imaging that democratize advanced measurement systems.
SPIE George W. Goddard Award in Space and Airborne Optics: John MacKenty
For leading the design, development, testing, and operations of the Wide-Field Camera 3 on the Hubble Space Telescope, and for pioneering contributions to multi-object spectroscopy from space.
SPIE G. G. Stokes Award in Optical Polarization: Miguel A. Alonso
For pioneering work in the mathematical description of unconventional and non-paraxial polarization states.
SPIE Chandra S. Vikram Award in Optical Metrology: Zeev Zalevsky
For key contributions to the invention of a laser-based, remote, nano-vibrations sensor with primary applications in biomedical sensing and diagnostics.
SPIE Frits Zernike Award for Microlithography: Anthony Yen
For three decades of contributions in advancing microlithography technology, including developing extreme-ultraviolet lithography for high-volume manufacture of semiconductor integrated circuits.
SPIE Diversity Outreach Award: Danuta Sampson
For outstanding achievements in international educational outreach and leadership of activities promoting public engagement and diversity in science.
SPIE Maria Goeppert Mayer Award in Photonics: Volker Sorger
For pioneering research and outstanding innovations in the research and development of photonic and nanophotonic devices and systems, and for community leadership.
SPIE Maiman Laser Award: Bo Gu
For critical innovations in industrial laser technology with numerous seminal and sustained contributions, and for being an accomplished laser-industry leader with widely recognized commercial success.
SPIE Early Career Achievement Award — Academic Focus: Carmelo Rosales-Guzmán
For significant and innovative technical contributions to the field of structured light and its applications, as well as for the promotion of science in developing countries.
SPIE Early Career Achievement Award — Industry/Government Focus: Fenglin Peng
For contributions enabling the first LCD-based VR product on the market, and for innovating a compact Pancake VR with better image quality, higher efficiency, and easier mass-production.
SPIE María J. Yzuel Educator Award: Alexis Spilman Vogt
For excellence in optics-technician and associate’s-degree education and training, and for being a superb strategic educator in addressing the needs of an underserved market.
SPIE Aden and Marjorie Meinel Technology Achievement Award: Wolfgang Fink
For pioneering, sustained contributions to the development of transformational opto-medical examination and device technologies, with particular focus on visual prostheses for the blind, ophthalmology, and tele-ophthalmology.
The complete listing of the SPIE Society Awards and recipients is available here.
About SPIE
SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, SPIE has contributed more than $22 million to the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development. www.spie.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230110005929/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents23.4.2026 13:29:00 CEST | Press release
Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agentsA manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designationThe program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by t
Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press release
New structure to drive AI-powered innovation and international expansion Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency
NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce23.4.2026 13:00:00 CEST | Press release
NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time. AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them. AI is Becoming the Operating Layer of Global Commerce NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what product
Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights23.4.2026 12:10:00 CEST | Press release
Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues,
REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements23.4.2026 12:05:00 CEST | Press release
Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);Group net profits of €250.9 million (€211.1 million in 2024).Approval of the proposal to distribute a dividend of €1.35 per share.Approval of the plan for the purchase and/or disposal of treasury shares. The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared to €2,300.5 million in 2024. Consolidated EBITDA was €467.6 million, up 13.9% compared to €410.6 million recorded for the year 2024. EBIT, from January to December, was €397.1 million, up 18.5% compared to €330.4 million recorded for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom